There are many interesting hurdles that impede and, at the same time, bolster your capabilities as a survivor. The mini-game-style quests that are scattered here and there around the map have the same purpose. When it comes to the Telephone Booth puzzle, it is less of a puzzle and more of a blind Source…
Almost 55 years after the launch of Apollo 11—the first mission to land humans on the moon—scientists have found evidence of a large cave system near the landing site of those astronauts…
New Zealand was once home to giant flightless birds called moa. They had grown accustomed to life without predators. So the arrival of humans in the mid-13th century presented a massive—and ultimately insurmountable—challenge to their existence…
Uncover the truth about AI in marketing and why it’s a ticking time bomb for unprepared businesses! As AI revolutionizes the marketing landscape, understanding its long-term impact is crucial…
The Balochistan government on Saturday said there were “unconfirmed rumours of firing by security forces” in Mastung as a hospital official confirmed that 14 people were injured. The Baloch Yakjehti Committee (BYC) is set to hold a gathering in Gwadar on Sunday, where leaders of different political parties and rights activists from across the country…
Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting of marketing authorization for Anzupgo (delgocitinib; LEO Pharma) to treat moderate to severe chronic hand eczema in adults when topical corticosteroids are insufficient. A final decision from the European Commission is now pending. Chronic hand eczema is an inflammatory skin condition of the…
A drug to treat severe itching in patients with Alagille syndrome should be granted a marketing authorization in the European Union under what the European Medicines Agency (EMA) termed exceptional circumstances. At its monthly meeting, the agency’s Committee for Medicinal Products for Human Use (CHMP) determined that Kayfanda (odevixibat…
The European Medicines Agency (EMA) has recommended strengthening existing advice to minimize the risks from interactions between Mysimba (naltrexone/bupropion; Orexigen Therapeutics Ireland Limited) and opioid-containing medicines. The recommendation followed a routine review of the safety of the weight loss medication. The EMA’s Committee for Medicinal Products for Human Use (CHMP) advised...